Omburtamab (CD276/B7-H3/B7RP-2) Antibody, Monoclonal | 10-915

Omburtamab (CD276/B7-H3/B7RP-2) Antibody, Monoclonal | 10-915 | Gentaur UK, US & Europe Distribution

Host: N/A

Reactivity: N/A

Homology: N/A

Immunogen: Mus musculus / CD276/B7-H3/B7RP-2 [Homo sapiens]

Research Area: Drug Analogues

Tested Application: N/A

Application: N/A

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: >95%

Clonality: Monoclonal

Clone: N/A

Isotype: IgG1-kappa

Conjugate: Unconjugated

Physical State: N/A

Buffer: PBS buffer pH7.5

Concentration: N/A

Storage Condition: Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚C for 1-2 weeks. Store at -20 ˚C for 12 months. Store at -80 ˚C for long term storage.

Alternate Name: 8H9, Mab 8H9

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: Omburtamab is monoclonal antibody targeting B7-H3 antigen expressed in a variety of human solid tumors. Omburtamab (alias: 8H9, formerly known as Burtomab) is a monoclonal antibody linked to radioisotope and capable of binding to the B7-H3 antigen on the surface of neuroblastoma cells. Direct injection into cerebrospinal fluid, bypassing the blood-brain barrier, accurately targeting neuroblastoma in the central nervous system, to avoid damage to other tissues (such as learning disabilities and developmental delays often caused by conventional radiotherapy outside the brain) .